发明名称 |
Quinazoline derivatives as VEGF inhibitors |
摘要 |
The invention relates to quinazoline derivatives of formula (I),;
wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3, wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3, wherein R3 is as defined herein; 3) C2-5alkynylR3, wherein R3 is as defined herein; and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation; pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. |
申请公布号 |
US9040548(B2) |
申请公布日期 |
2015.05.26 |
申请号 |
US201414146954 |
申请日期 |
2014.01.03 |
申请人 |
AstraZeneca AB |
发明人 |
Thomas Andrew Peter;Stokes Elaine Sophie Elizabeth;Hennequin Laurent Francois Andre |
分类号 |
A01N43/54;A61K31/517;C07D239/72;C07D401/00;C07D401/12 |
主分类号 |
A01N43/54 |
代理机构 |
Morgan, Lewis & Bockius LLP |
代理人 |
Morgan, Lewis & Bockius LLP |
主权项 |
1. A method of treating breast cancer in a warm-blooded animal in need of such treatment which comprises administering to the animal an effective amount of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline or a pharmaceutically acceptable salt thereof. |
地址 |
Sodertalje SE |